KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accumulated Expenses (2016 - 2025)

Inovio Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $955970.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 78.74% year-over-year to $955970.0; the TTM value through Sep 2025 reached $955970.0, down 78.74%, while the annual FY2024 figure was $2.0 million, 14.52% down from the prior year.
  • Accumulated Expenses for Q3 2025 was $955970.0 at Inovio Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $13.6 million in Q3 2021 and bottomed at $955970.0 in Q3 2025.
  • The 5-year median for Accumulated Expenses is $5.5 million (2024), against an average of $6.5 million.
  • The largest annual shift saw Accumulated Expenses skyrocketed 133.15% in 2021 before it plummeted 78.74% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $10.3 million in 2021, then grew by 2.59% to $10.6 million in 2022, then tumbled by 77.67% to $2.4 million in 2023, then dropped by 14.52% to $2.0 million in 2024, then crashed by 52.72% to $955970.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Accumulated Expenses are $955970.0 (Q3 2025), $1.5 million (Q2 2025), and $1.8 million (Q1 2025).